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Prognostic Factors After Combined Modality Treatment of
Squamous Cell Carcinoma of the Esophagus
Nabil P. Rizk, MD,* Venkatraman E. Seshan, PhD,¶ Manjit S. Bains, MD,* David H. Ilson, MD,†
Bruce D. Minsky, MD,‡ Laura Tang, MD, and Valerie W. Rusch, MD*
Introduction: In a previous study of prognostic factors in patients
with loco-regionally advanced adenocarcinoma of the esophagus
treated with chemo-radiotherapy (CRT) followed by resection, we
found that residual nodal disease was most prognostic of outcome.
In this study, we evaluated prognostic factors among patients with
squamous cell carcinoma (SCC) of the esophagus who have under-
gone a similar treatment regimen.
Methods: A retrospective review of patients with SCC of the
esophagus who received CRT before esophagectomy. Data collected
included demographics, CRT details, pathologic findings, and sur-
vival. Statistical methods included recursive partitioning and
Kaplan-Meier analyses.
Results: From 1996 to 2006, 91 patients were appropriate for this
analysis. Complete pathologic response in the primary tumor (pt-
pCR) occurred in 49 patients (53.8%), including 10 of 91 (10.9%)
who had a pt-pCR but residual nodal disease. Recursive partitioning
analysis identified three prognostic groups: (1) group 1 (n  52),
patients with minimal residual local disease (pt-pCR and T1-N any);
(2) group 2 (n  28), patients with residual T2 disease (N0 and N1)
and patients with T3-4N0 disease; and (3) group 3 (n 11), patients
with residual T3-4N1 disease. Three-year survival was 68.4% in
group 1, 45.6% in group 2, and 0 % in group 3 (p  0.001).
Conclusions: Unlike adenocarcinoma, in which residual nodal disease
after CRT is the most significant predictor of survival, in SCC of the
esophagus, pt-pCR or minimal residual local disease after CRT predicts
the best survival. These findings aid the design of future clinical trials.
Key Words: Esophageal squamous cell cancer, Chemoradiation,
Prognostic variables.
(J Thorac Oncol. 2007;2: 1117–1123)
Most studies of induction therapy followed by surgery forthe treatment of loco-regionally advanced esophageal
cancer do not distinguish among tumor histologic types and
their potential dissimilarities in response to treatment or
posttreatment prognostic factors. Published data suggest that
esophageal squamous cell carcinomas (SCC) may respond
differently to induction chemoradiotherapy (CRT) than
esophageal adenocarcinomas,1–3 especially with respect to
the likelihood of a complete pathologic response (pCR). pCR
is commonly used to measure treatment response and is often
associated with improved survival relative to patients who
have residual disease.4 Although the frequency of pCR is
difficult to compare among studies for various reasons, in-
cluding the lack of distinction between tumor histologies,
varying radiation doses, and different pretreatment clinical
stage, pCR rates in adenocarcinoma are generally in the range
of 20% to 30%, whereas in SCC, pCR occurs in up to 50% of
patients.3–8 Whereas a pCR is commonly associated with
improved survival,2,8–11 this difference in pCR rates does not
seem to translate into better overall outcomes in SCC after
CRT in most studies.1,12–15 This discrepancy raises the pos-
sibility that additional factors influence survival in these two
tumor histologies.
We recently reported our analysis of prognostic factors
among patients with adenocarcinoma of the esophagus un-
dergoing CRT and surgery.16 Results from that analysis
showed that after CRT, AJCC tumor stage did not predict
survival accurately, that residual nodal disease was the most
important prognostic factor, and that the presence of residual
primary tumor had less influence on survival. Other studies
corroborate our findings.17 In the current study, we perform a
similar analysis among patients with SCC of the esophagus to
identify important prognostic factors that might be used as
end points in selecting patients for resection and in designing
future clinical trials.
METHODS
Acquisition of Clinical Data
We undertook a retrospective review of all patients
undergoing resection for SCC of the esophagus at Memorial
Sloan-Kettering Cancer Center between January 1996 and
February 2006. January 1996 is when an institutional elec-
tronic medical record system was instituted and is therefore a
time from which highly reliable data can be obtained. Patients
who did not have survival information available were ex-
cluded from this analysis. We also excluded any patient who
did not undergo preoperative chemotherapy with radiation or
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who received definitive nonsurgical treatment but eventually
underwent surgery as salvage therapy.
The data collected included patient age, preoperative
clinical stage (based on a combination of radiographic and
endoscopic studies), type of preoperative therapy (type of
chemotherapy, amount of radiation, length of time from the
completion of radiation to surgery), depth of tumor invasion,
estimated treatment effect, and the number of all malignant
and benign lymph nodes. Overall survival, as calculated from
the time of operation, was obtained from the electronic
records at Memorial Sloan-Kettering Cancer Center and con-
firmed from the Social Security Death Index. June 1, 2006,
was the censoring date for survival.
Clinical Stage
Patients treated with preoperative chemoradiotherapy
at our institution are all deemed to have loco-regionally
advanced disease. Confirmation of clinical stage was ob-
tained with a combination of computed tomography (CT),
positron emission tomography (PET), and endoscopic ultra-
sound (EUS). Evidence of lymph node involvement by CT,
PET, or EUS and evidence of a T3 lesion by EUS were used
to confirm T3, N1, or M1a or some combination of these T,
N, M stages (stages IIa to IVa).
TNM Classification
The T, N, and M descriptors and staging classification
used for this analysis were those defined in the sixth edition
of the AJCC Cancer Staging Manual.18 Because of some
variations in the nomenclature used by surgeons and pathol-
ogists in identifying the exact location of lymph nodes within
a resected specimen, lymph nodes were consistently identi-
fied as “celiac axis” if they were labeled as left gastric,
splenic, celiac, or hepatic. Within the chest, lymph nodes
were identified as subcarinal lymph nodes if they were
labeled as either level 7, left mainstem, or right mainstem.
M1a nodes were labeled according to the primary tumor
location. Celiac axis nodes were M1a for distal esophageal,
gastroesophageal junction, and gastric cardia tumors that
involved the gastroesophageal junction. Cervical lymph
nodes were M1a for tumors of the proximal third of the
esophagus. The total number of involved lymph nodes in-
cluded any positive lymph node found excluding remote
nodes that would be assigned as M1b. The overall number of
lymph nodes included the sum of all malignant and benign
lymph nodes found. Disease was considered M1b if nodes
were positive outside the regional basin or if visceral metas-
tases were identified. The depth of primary tumor invasion
was assigned as described in the AJCC staging manual. A
complete response was considered to have occurred when no
evidence of viable tumor was noted (i.e., T0N0). Patients
with T0N1 disease were categorized as having stage IIb
disease. In the analyses that used the number of involved
lymph nodes as variables, the nomenclature used to distin-
guish this from the AJCC nodal system is N(#).
Estimation of Pathologic Complete Response
The gross appearance of treated tumors varied from
mucosal ulceration to a fibrous scar, or a prominent mass
lesion in the case of a less than profound tumor regression.
Photographs of the gross specimen were taken for all cases.
The ulcerated or the scarred gross lesion at gastroesophageal
junction was blocked, sequentially and entirely submitted for
histopathological evaluation. When the tumor was large in
size (5.0 cm), only representative sections of the tumor
were examined microscopically. At the microscopic level, a
positive treatment related-effect was observed as abolition of
the malignant epithelium and replacement by reactive fibrosis
or fibro-inflammation within the mucosa or the gastroesoph-
ageal wall. The ultimate pathological response to treatment
was thus determined by the amount of residual viable carci-
noma in relation to areas of fibrosis or fibro-inflammation
within the gross lesion, which was inversely associated with,
and expressed as percentage of, a favorable treatment re-
sponse. Thus, a 100% treatment response indicated fibrosis or
fibro-inflammation within an entire gross lesion without mi-
croscopic evidence of carcinoma. A pCR was assigned when
there was both a 100% local treatment response and no
evidence of residual nodal involvement. A pCR in the pri-
mary tumor (pt-pCR) was assigned when there was a 100%
treatment response in the primary tumor but evidence of
residual viable nodal disease.
Statistical Analysis
Patient characteristics are described using tables for
categorical data and medians and range for continuous vari-
ables. Survival time was measured from the date of surgery to
the date of death or last follow-up. Survival curves were
estimated using the Kaplan-Meier method. Maximal log rank
analysis19 was used to determine the optimal cutoffs for
lymph node numbers. Recursive partitioning20 was used to
develop a scheme to classify patients into stage categories.
We used recursive partitioning modeling because the goal of
a staging system is to group the patients into homogenous
categories with respect to their prognosis (in this case, sur-
vival). Because several clinical characteristics (T, N, M,
lymph node numbers) affect the prognosis of a patient, using
traditional multivariable modeling such as Cox proportional
hazards regression to account for these covariates does not
provide a simple way to group the patients by prognosis
categories. Recursive partitioning, however, partitions pa-
tients recursively at each step into two groups based on the
covariate that gives the maximal separation with respect to
their prognosis. In addition to providing an algorithm by
which to group the patients into categories, it accounts for
interactions among factors. Thus, recursive partitioning was
used to develop a scheme to classify patients into stage
categories. Recursive partitioning was performed using the
RPART routines of Therneau and Atkinson.21 This algorithm
partitions after scaling the survival times so as to fit an
exponential model and the hazard rate in the “exponential-
scaled” times of terminal nodes are reported.
RESULTS
Clinical Data
During the study period, 856 esophagectomies were
performed, and 91 patients were appropriate for this analysis.
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One patient meeting the analysis criteria was excluded be-
cause of lack of survival information. Ten patients were
excluded because they underwent a palliative esophagec-
tomy. Early clinical stage disease or other tumor type caused
401 patients to be excluded. Sixty patients were excluded
because they received preoperative chemotherapy only under
a previous protocol. The rest who were excluded (n  393)
all had adenocarcinoma and underwent preoperative chemo-
radiation. The median patient age was 62.1 years (range,
22.3–79.7 yr), and 35 patients were female (38.5%). Of the
91 patients included, 78 patients who received preoperative
radiotherapy had adequate treatment information. Sixty-three
(80.8%) were treated with a total dose of 5040 cGy (180 cGy
daily in 28 fractions). Most patients (n  85, 93.4%)
received various concurrent cisplatin-based chemotherapy
regimens, according to sequential clinical trials performed
during this time frame (Tables 1 and 2).22
Outcome in Patients with a Pathologic
Complete Response to Induction Therapy
The R0 resection rate was 93.4%. Overall, 49 of 91
patients (53.8%) had evidence of a pt-pCR. Of these 49
patients, 10 had persistent nodal involvement; thus, 39 pa-
tients had a pCR (42.8%). The survival of patients with a
pt-pCR was significantly better (p  0.01) than that of
patients with residual disease in the primary tumor (3-year
survival of 68.5 vs 39.0 months, respectively). Although the
number of patients analyzed is small, the involvement of
lymph nodes in patients with a pt-pCR (n  10) does not
seem to influence survival compared with patients who had a
pCR (n  39) (p  0.45) (Figure 1).
Recursive Partitioning Analysis of T, N, M
Recursive partitioning, using T, N, and M as variables,
indicates that the principal determinant of improved survival
is the presence of either a pt-pCR or of minimal residual local
disease (T1 disease or less) (Figure 2). This group (group 1)
is primarily composed of patients with a local pCR (pCR
regardless of nodal status), with an additional smaller subset
of patients consisting of two patients with carcinoma in situ
and two patients with T1 disease. Of note, there were no
TisN1 or T1N1 patients. The next prognostic group (group 2)
is composed of patients with T2 disease regardless of nodal
status and of patients with T3N0 disease. The worst prognos-
tic group (group 3) showed minimal evidence of local treat-
ment response and consisted of patients with T3N1 and T4N1
disease. Notably, these three prognostic groups all had similar
clinical stages before treatment (Table 3).
Percent Treatment Response
Within the three prognostic groups identified in the
recursive partitioning analysis, the estimated treatment re-
sponse was best in group 1 and least in group 3 (Table 3). Of
note, there was no statistical correlation between nodal status
and treatment response in the primary tumor. Posttreatment
node-negative patients had a mean treatment response in the
primary tumor of 81.2%, and posttreatment node-positive
patients had a mean treatment response in the primary tumor
of 63.7% (p  0.07).
Impact of Positive Lymph Nodes
Emphasizing the fact that the presence of residual nodal
disease has a minor impact on survival in SCC of the
esophagus after CRT, an analysis of survival based on the
number of positive lymph nodes shows that within the range
of zero to four involved nodes, survival is not appreciably
TABLE 1. Patient Characteristics
Characteristic Patients (n) %
Total 91
Sex (F) 35 38.5
Age (yr) 62.1 (22.3–79.5)
Staging
CT scan 91 100
PET (pre-, post-, or both) 69 75.8
EUS 53 58.2
RT dose (Gy) 50.40 (27–60)
Time from RT to surgery (days) 56.5 (11–188)
Chemotherapy
Cisplatin-paclitaxel 45 49.5
Cisplatin-irinotecan 20 22.0
Cisplatin-5 fluorouracil 13 14.3
Other 13 14.3
Procedure type
McKeown 23 25.2
Ivor Lewis 55 60.4
Transhiatal 13 14.3
Tumor location
Proximal third 9 9.9
Middle third 33 36.3
Distal third 49 53.8
Data are expressed as n or median (range). RT, radiation.
TABLE 2. Pathologic Stage in Relationship to Treatment
Response and Prognostic Group Categories
Patients T N
AJCC
Stage pt-pCR*
% Tx
Response
Prognostic
Groupa
39 0 0 0 Yes 100 1
9 1 IIb Yes 100 1
2 is 0 0 Yes 95 1
0 1 IIb b b b
2 1 0 I No 96.5 1
0 1 IIb b b b
8 2 0 IIa No 74.4 2
5 1 IIb No 62.8 2
15 3 0 IIb No 27.3 3
9 1 III No 20.7 3
0 4 0 IIb b b b
2 1 III No 5 3
pt-pCR, Pathologic complete response in the primary tumor.
aBased on recursive partitioning analysis.
bNo patients in group.
Tx, Treatment.
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different (Figure 3). Patients with five or more positive nodes
do worse, although there were few patients in this group (n 5).
When the patients who had metastases in five or more nodes are
excluded from the analysis, survival is the same regardless of
whether nodes are positive (p  0.26, figure not shown).
DISCUSSION
Our recently published results on the prognostic
characteristics of adenocarcinoma of the esophagus after
CRT indicated that nodal status rather than overall TNM
stage was the most important predictor of survival and that
the depth of the residual primary tumor (T stage) was much
less predictive of outcome. In addition, this analysis found
that only 20% of patients with adenocarcinoma had a pCR
after treatment.16 In the current study, we showed that SCC
of the esophagus has different post-CRT prognostic char-
acteristics than adenocarcinoma. We found that the most
important prognostic factor after CRT is the presence of
minimal residual local disease. Nodal status seems to have
minimal influence on outcome, although the number of
FIGURE 1. Survival of patients with a
local pathologic complete response
(pCR) compared with residual disease
(pt-pCR).
FIGURE 2. Recursive partitioning us-
ing T, N, M as variables.
TABLE 3. Prognostic Group Characteristics
Group
Mean Tx
Effect (%)
3-yr
Survival (%)
5-yr
Survival (%)
1 (n  52) 99.7 68.4 52.0
2 (n  28) 48.6 45.6 45.6
3 (n  11) 18.8 18.2 0.0
Tx, Treatment.
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patients is too small to draw any firm conclusions. This
group of patients represents 57.1% of treated patients,
most of whom have had a pt-PCR, and all of whom have
evidence of a significant treatment response (mean 99.7%).
The 3-year and 5-year survivals of this group of patients
are highly favorable at 68% and 52%, respectively. In
contrast, the worst prognostic group showed minimal ev-
idence of local treatment response and included T3N1 and
T4N1 tumors. This subset of patients had a mean estimated
treatment response of only 18.7%. Median survival of
these patients was only 9.4 months, and all patients were
dead by 40 months.
FIGURE 3. Survival of patients rela-
tive to number of positive lymph
nodes.
TABLE 4. Summary of Studies of Combined Modality Therapy for Esophageal Carcinoma
Studies Including Both Adeno and Squamous Cell Carcinoma
Author Histology Radiation Dose (Gy) Chemotherapy pCR (%)
Burmeister et al.3 SCC (80)
ADA (45)
35 C, F 228
Schneider et al.8 SCC (46)
ADA (28)
36 C, F 1815
Slater et al.5 SCC (7)
ADA (26)
40 C, F 438
De Vita et al.6 SCC (26)
ADA (13)
40 C, F 350
Stahl et al.7 SCC (43)
ADA (9)
40 C, F, E, L 51
22
Wolfe et al.11 SCC (72)
ADA (93)
45 C, VC, F 40
20
Adelstein et al.12 SCC (24)
ADA (48)
45 C, F 36
22
Jones et al.13 SCC (39)
ADA (15)
45 C, F 43
33
Studies including only one tumor histology
Le Prise et al.27 SCC (41) 20 C, F 10
Seydel et al.28 SCC (41) 30 C, F 30
Bosset et al.25 SCC (112) 37 C 26
Walsh et al.29 ADA (113) 40 C, F 25
Donington et al.4 ADA (47) 45 C, F 26
Rizk et al.16 ADA (240) 50.4 C, F or C, CPT11 or C, paclitaxel 20
Current study SCC (91) 50.4 C, F, or C, CPT11 or C, paclitaxel 53.8
C, cisplatin; F, 5-fluorouracil; L, leucovorin; V, vincristine; CPT11, irinotecan; P, paclitaxel.
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Interestingly, the published literature rarely makes a
distinction between SCC and adenocarcinoma of the esoph-
agus, usually combining these two tumor types in retrospec-
tive analyses and in clinical trials, despite the fact that the
etiology of these two diseases is clearly recognized as differ-
ent,3 and that the management of SCC in other sites of the
digestive tract such as head and neck23 and anal SCC24 is
primarily chemoradiotherapy without resection. For these
patients, surgery is used only as salvage therapy. In the five
major prospective randomized clinical trials comparing CRT
with surgery alone for esophageal cancer, three were done for
SCC only, one for adenocarcinoma only, and two for patients
with both tumor types. This distribution of tumor type was
primarily a reflection of the predominant disease patterns at
the time of the study rather than from any conscious recog-
nition of differences between the two histologies. Among the
studies that examined only SCC,25–27 all used suboptimal
radiation doses, and two studies treated patients with sequen-
tial rather than concurrent chemoradiation, making the results
of these studies difficult to interpret within the context of
current chemoradiation protocols. The two trials that included
both tumor histologies show results similar to ours. In the
report by Urba et al.,2 no explicit data are provided regarding
responses to treatment by tumor histology, but mention is
made of the fact that in an earlier trial,9 in which a larger
proportion of patients had SCC (25% vs. 51%), patients
treated with CRT did relatively better than in the current trial,
suggesting that SCC might be more responsive to treatment.
In a trial reported by Burmeister et al., the investigators noted
a higher incidence of pCR in SCC, as well as a survival
benefit of CRT in SCC but not in adenocarcinoma. The
authors suggest that perhaps the vigorous response of SCC to
CRT explains why clinical trials have found similar survival
outcomes in patients undergoing CRT plus surgery compared
with CRT alone.3
The focus of many retrospective studies in evaluating
pathologic response to CRT has been the attribution of
posttreatment pCR as a marker of better prognosis. The
reported pCR rates in the literature vary widely but are
generally higher in patients who receive higher radiation
doses and in patients with SCC (Table 4). The difference in
pCR rates between SCC and adenocarcinoma is more obvious
in studies that use higher radiation doses (Table 4). In our
study, all patients had loco-regionally advanced disease, and
all had similar doses of radiation. Furthermore, the radiation
dose was similar to that commonly given when CRT is used
as definitive treatment.
The literature is similarly inconsistent in its findings on
the benefits of achieving a pCR. Specifically, some studies
indicate that a pCR correlates with better survival,2,8,9,11
whereas others do not.10 Some of this variability may be
related to the various proportions of tumor histologies and
pretreatment stages in these studies, as well as different
radiation doses administered. In addition, as we show in this
study, rather than focusing only at pCR rates, it seems that
evaluating patients for the presence of pt-pCR or minimal
residual disease in the primary tumor is a more accurate way
to identify patients with a better prognosis.
The major limitation of this study is that it is a retro-
spective analysis of a relatively small number of patients
from a single institution. Validation of these results are
needed from other datasets.
In summary, our study shows that a significant subset
of patients with esophageal SCC with loco-regionally ad-
vanced disease respond dramatically to what is commonly
considered to be definitive chemoradiotherapy. In contrast to
our previous publication on esophageal adenocarcinoma, the
characteristic that identifies favorable posttreatment progno-
sis in SCC is a significant treatment response in the primary
tumor, rather than evidence of residual nodal disease. These
findings can aid in the design of future clinical trials and
suggest that patients should be selected or stratified by tumor
histology. In addition, given the high response to nonsurgical
treatment, future randomized trials comparing CRT with
CRT plus surgery may best be performed in patients with
SCC rather than adenocarcinoma.
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